股本结构
单位：万股
| 公告日期 | 2026-10-07 | 2026-08-31 | 2026-09-08 | 2026-08-12 | 2026-08-12 | 2026-08-13 |
|---|---|---|---|---|---|---|
| 证券总股本 | 524.15 | 438.05 | 438.05 | 394.91 | 394.91 | 379.37 |
| 普通股本 | 524.15 | 438.05 | 438.05 | 394.91 | 394.91 | 379.37 |
| 优先股 | 未披露 | 0.82 | 未披露 | 0.82 | 未披露 | 0.82 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2026-09-29 | 2026-08-31 | 2026-08-28 | 2026-08-11 | 2026-08-10 | 2026-06-30 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2026-10-07 | 524.15 | 未披露 | 定期报告 | 2026-09-29 |
| 2026-08-31 | 438.05 | 0.82 | 定期报告 | 2026-08-31 |
| 2026-09-08 | 438.05 | 未披露 | 定期报告 | 2026-08-28 |
| 2026-08-12 | 394.91 | 0.82 | 定期报告 | 2026-08-11 |
| 2026-08-12 | 394.91 | 未披露 | 定期报告 | 2026-08-10 |
| 2026-08-13 | 379.37 | 0.82 |
更多>>
From March 31,2026 to June 30,2026
Cancellation of restricted common stock
Cash in lieu of shares
Conversion of Series D Preferred Stock to Common Stock
Conversion of Series E Preferred Stock to Common Stock
Issuance of common stock in connection with the ELOC
|
2026-06-30 |
| 2026-06-09 | 369.15 | 0.82 | 定期报告 | 2026-06-09 |
| 2026-06-09 | 369.15 | 未披露 | 定期报告 | 2026-06-05 |
| 2026-05-19 | 114.00 | 未披露 |
更多>>
a 1-for-10 reverse stock split of its outstanding shares of common stock
|
2026-05-21 |
| 2026-05-19 | 1140.00 | 未披露 | 定期报告 | 2026-05-19 |
| 2026-04-28 | 1146.46 | 未披露 | 定期报告 | 2026-04-24 |
| 2026-05-13 | 275.52 | 1.75 |
更多>>
From December 31, 2025 to March 31, 2026
Conversion of Series E Preferred Stock to Common Stock
Conversion of Series D Preferred Stock to Common Stock
Issuance of Common Stock for Warrant Exercise
Cancellation of restricted common stock
Cash in lieu of shares
|
2026-03-31 |
| 2026-03-30 | 69.29 | 未披露 |
更多>>
a 1-for-5 reverse stock split of its outstanding shares of common stock
|
2026-03-25 |
| 2026-03-23 | 360.00 | 未披露 | 定期报告 | 2026-03-23 |
| 2026-03-13 | 358.42 | 未披露 | 定期报告 | 2026-03-11 |
| 2026-03-13 | 156.00 | 2.41 |
更多>>
From December 31, 2024 to December 31, 2025
Issuance of Series D Preferred Stock
Exchange of Series C Preferred Stock to Series D Preferred Stock
Conversion of Series D Preferred Stock to common stock
Issuance of Series E Preferred Stock
Issuance of common stock in connection with the ELOC
Cash in lieu of shares
Issuance of restricted common stock
Conversion of Series C Preferred shares to common stock
Cancellation of restricted common stock
Cancellation of Cede & Co. Shares
Settlement of subscription agreement liability
|
2025-12-31 |
| 2025-12-22 | 155.50 | 2.41 | 定期报告 | 2025-12-22 |
| 2026-01-02 | 155.50 | 未披露 | 定期报告 | 2025-12-12 |
| 2025-11-13 | 156.07 | 未披露 | 定期报告 | 2025-11-12 |
| 2025-11-04 | 155.50 | 2.41 | 定期报告 | 2025-11-04 |
| 2025-11-10 | 155.50 | 未披露 | 定期报告 | 2025-10-21 |
| 2025-11-13 | 156.07 | 1.63 |
更多>>
From June 30, 2025 to September 30, 2025
Issuance of restricted common stock
Issuance of Series D Preferred Stock
Exchange of Series C Preferred Stock to Series D Preferred Stock
Conversion of Series D Preferred Stock to common stock
Cancellation of restricted common stock
|
2025-09-30 |
| 2025-08-14 | 154.57 | 未披露 | 定期报告 | 2025-08-13 |
| 2025-08-14 | 100.90 | 0.21 |
更多>>
From March 31, 2025 to June 30, 2025
Issuance of common stock in connection with the ELOC
Cash in lieu of shares
Settlement of subscription agreement liability
|
2025-06-30 |
| 2025-06-11 | 52.19 | 未披露 |
更多>>
a 1-for-85 reverse stock split of its outstanding shares of common stock
|
2025-06-13 |
| 2025-06-12 | 4435.84 | 未披露 | 定期报告 | 2025-06-12 |
| 2025-06-11 | 4440.00 | 未披露 | 定期报告 | 2025-06-11 |
| 2025-04-30 | 4435.84 | 未披露 | 定期报告 | 2025-04-14 |
| 2025-06-12 | 3676.11 | 0.21 |
更多>>
From December 31, 2024 to March 31, 2025
Issuance of common stock in connection with the ELOC
|
2025-03-31 |
| 2025-02-12 | 1454.52 | 0.35 | 定期报告 | 2025-02-11 |
| 2025-01-27 | 1454.52 | 未披露 | 定期报告 | 2025-01-22 |
| 2025-06-02 | 1175.45 | 0.35 |
更多>>
From December 31, 2023 to December 31, 2024
Issuance of common stock and warrants from exercise of preferred investment options, net of issuance costs
Grant and immediate exercise of warrants
Issuance of shares in connection with related party subscription agreement
Conversion of Series A Preferred Stock to common stock
Conversion of Series B Preferred Stock to common stock
Exercise of stock options
Issuance of restricted common stock
Forfeitures of restricted stock
Cash in lieu of shares
Issuance of common stock in connection with the ELOC
Issuance of restricted common stock in exchange in exchange for options
|
2024-12-31 |
| 2024-10-31 | 829.47 | 0.35 | 定期报告 | 2024-10-11 |
| 2024-12-10 | 831.33 | 未披露 |
更多>>
From June 30, 2024 to September 30, 2024
Issuance of common stock and warrants from exercise of preferred investment options, net of issuance costs
Issuance of restricted stock
Exercise of pre-funded warrants
Conversion of Series A Preferred Stock to common stock
Conversion of Series B Preferred Stock to common stock
Issuance of shares and pre-funded warrants in connection with related party subscription agreement
|
2024-09-30 |
| 2024-09-20 | 829.41 | 未披露 |
更多>>
1-for-40 reverse stock split of its outstanding shares of common stock
|
2024-09-24 |
| 2024-09-20 | 2968.39 | 未披露 | 定期报告 | 2024-09-20 |
| 2024-08-29 | 2979.01 | 未披露 | 定期报告 | 2024-08-29 |
| 2024-08-01 | 2968.39 | 未披露 | 定期报告 | 2024-07-31 |
| 2024-07-11 | 2979.01 | 未披露 |
更多>>
July 12, 2024 Onconetix, Inc, today announced it has entered into definitive agreements for the immediate exercise of certain existing warrants to purchase 7,458,642 shares.
|
2024-07-12 |
| 2024-07-03 | 2233.15 | 269.97 | 定期报告 | 2024-07-03 |
| 2024-08-29 | 2233.15 | 269.97 |
更多>>
From March 31, 2024 to June 30, 2024
Issuance of restricted stock
|
2024-06-30 |
| 2024-06-25 | 2232.77 | 269.97 | 定期报告 | 2024-06-24 |
| 2024-04-11 | 2232.77 | 未披露 | 定期报告 | 2024-04-11 |
| 2024-04-11 | 2218.67 | 未披露 | 定期报告 | 2024-04-05 |
| 2024-05-20 | 2232.77 | 269.97 |
更多>>
From December 31, 2023 to March 31, 2024
Issuance of restricted stock
|
2024-03-31 |
| 2024-04-11 | 2232.46 | 269.97 |
更多>>
From December 31, 2022 to December 31, 2023
Exercise of stock options
Purchase of treasury shares
Issuance of common stock from exercise of preferred investment options
Exercise of pre-funded warrants
Issuance of restricted stock
Issuance of common stock and Series B Preferred Stock in connection with PMX Transaction
Issuance of Series A Preferred Stock
Forfeitures of restricted stock
|
2023-12-31 |
| 2023-11-17 | 1865.54 | 未披露 | 定期报告 | 2023-11-17 |
| 2023-10-20 | 1798.81 | 未披露 | 定期报告 | 2023-10-20 |
| 2023-11-17 | 1781.92 | 未披露 |
更多>>
From June 30, 2023 to September 30, 2023
Issuance of common stock from exercise of preferred investment options
Restricted stock forfeitures
|
2023-09-30 |
| 2023-10-20 | 1641.31 | 未披露 |
更多>>
From March 31, 2023 to June 30, 2023
Exercise of stock options
Issuance of restricted stock
|
2023-06-30 |
| 2023-05-12 | 1590.57 | 未披露 | 定期报告 | 2023-05-12 |
| 2023-04-26 | 1587.82 | 未披露 | 定期报告 | 2023-04-03 |
| 2023-05-12 | 1587.92 | 未披露 |
更多>>
From December 31, 2022 to March 31, 2023
Exercise of pre-funded warrants
Purchase of treasury shares
|
2023-03-31 |
| 2023-03-29 | 1590.20 | 未披露 | 定期报告 | 2023-03-22 |
| 2023-03-09 | 1591.19 | 未披露 | 定期报告 | 2023-03-06 |
| 2023-03-09 | 1526.52 | 未披露 |
更多>>
From December 31, 2021 to December 31, 2022
Issuance of common stock in initial public offering, net of $2.9 million of offering costs
Conversion of convertible preferred stock to common stock upon initial public offering
Issuance of common stock and warrants in April private placement, net of $1.1 million of offering costs
Issuance of common stock and warrants in August private placement, net of $2.2 million of offering costs
Exercise of stock options
Exercise of pre-funded warrants
Issuance of restricted common stock
Purchase of treasury shares
|
2022-12-31 |
| 2022-11-14 | 1547.50 | 未披露 | 定期报告 | 2022-11-14 |
| 2022-11-14 | 1468.99 | 未披露 |
更多>>
From June 30, 2022 to September 30, 2022
Exercise of pre-funded warrants
Exercise of stock options
Issuance of common stock and warrants in private placement, net of $2.2 million of offering costs
|
2022-09-30 |
| 2022-09-20 | 1374.49 | 未披露 | 定期报告 | 2022-09-19 |
| 2022-08-29 | 1369.80 | 未披露 | 定期报告 | 2022-08-29 |
| 2022-08-11 | 1357.94 | 未披露 |
更多>>
At the closing of the Private Placement, the Company issued 1,350,000 shares of common stock
|
2022-08-11 |
| 2022-08-15 | 1222.94 | 未披露 |
更多>>
From March 31, 2022 to June 30, 2022
Exercise of pre-funded warrants
Issuance of common stock and warrants in private placement, net of $1.1 million of offering costs
|
2022-06-30 |
| 2022-05-03 | 1163.90 | 未披露 | 定期报告 | 2022-05-03 |
| 2022-05-13 | 1104.86 | 未披露 |
更多>>
From December 31, 2021 to March 31, 2022
Issuance of common stock in initial public offering, net of $2.9 million of offering costs
Conversion of convertible preferred stock to common stock upon initial public offering
|
2022-03-31 |
| 2022-02-23 | 1104.86 | 未披露 |
更多>>
1.Common stock offered by company 2,222,222 shares.
|
2022-02-18 |
From March 31,2026 to June 30,2026
Cancellation of restricted common stock
Cash in lieu of shares
Conversion of Series D Preferred Stock to Common Stock
Conversion of Series E Preferred Stock to Common Stock
Issuance of common stock in connection with the ELOC
a 1-for-10 reverse stock split of its outstanding shares of common stock
From December 31, 2025 to March 31, 2026
Conversion of Series E Preferred Stock to Common Stock
Conversion of Series D Preferred Stock to Common Stock
Issuance of Common Stock for Warrant Exercise
Cancellation of restricted common stock
Cash in lieu of shares
a 1-for-5 reverse stock split of its outstanding shares of common stock
From December 31, 2024 to December 31, 2025
Issuance of Series D Preferred Stock
Exchange of Series C Preferred Stock to Series D Preferred Stock
Conversion of Series D Preferred Stock to common stock
Issuance of Series E Preferred Stock
Issuance of common stock in connection with the ELOC
Cash in lieu of shares
Issuance of restricted common stock
Conversion of Series C Preferred shares to common stock
Cancellation of restricted common stock
Cancellation of Cede & Co. Shares
Settlement of subscription agreement liability
From June 30, 2025 to September 30, 2025
Issuance of restricted common stock
Issuance of Series D Preferred Stock
Exchange of Series C Preferred Stock to Series D Preferred Stock
Conversion of Series D Preferred Stock to common stock
Cancellation of restricted common stock
From March 31, 2025 to June 30, 2025
Issuance of common stock in connection with the ELOC
Cash in lieu of shares
Settlement of subscription agreement liability
a 1-for-85 reverse stock split of its outstanding shares of common stock
From December 31, 2024 to March 31, 2025
Issuance of common stock in connection with the ELOC
From December 31, 2023 to December 31, 2024
Issuance of common stock and warrants from exercise of preferred investment options, net of issuance costs
Grant and immediate exercise of warrants
Issuance of shares in connection with related party subscription agreement
Conversion of Series A Preferred Stock to common stock
Conversion of Series B Preferred Stock to common stock
Exercise of stock options
Issuance of restricted common stock
Forfeitures of restricted stock
Cash in lieu of shares
Issuance of common stock in connection with the ELOC
Issuance of restricted common stock in exchange in exchange for options
From June 30, 2024 to September 30, 2024
Issuance of common stock and warrants from exercise of preferred investment options, net of issuance costs
Issuance of restricted stock
Exercise of pre-funded warrants
Conversion of Series A Preferred Stock to common stock
Conversion of Series B Preferred Stock to common stock
Issuance of shares and pre-funded warrants in connection with related party subscription agreement
1-for-40 reverse stock split of its outstanding shares of common stock
July 12, 2024 Onconetix, Inc, today announced it has entered into definitive agreements for the immediate exercise of certain existing warrants to purchase 7,458,642 shares.
From March 31, 2024 to June 30, 2024
Issuance of restricted stock
From December 31, 2023 to March 31, 2024
Issuance of restricted stock
From December 31, 2022 to December 31, 2023
Exercise of stock options
Purchase of treasury shares
Issuance of common stock from exercise of preferred investment options
Exercise of pre-funded warrants
Issuance of restricted stock
Issuance of common stock and Series B Preferred Stock in connection with PMX Transaction
Issuance of Series A Preferred Stock
Forfeitures of restricted stock
From June 30, 2023 to September 30, 2023
Issuance of common stock from exercise of preferred investment options
Restricted stock forfeitures
From March 31, 2023 to June 30, 2023
Exercise of stock options
Issuance of restricted stock
From December 31, 2022 to March 31, 2023
Exercise of pre-funded warrants
Purchase of treasury shares
From December 31, 2021 to December 31, 2022
Issuance of common stock in initial public offering, net of $2.9 million of offering costs
Conversion of convertible preferred stock to common stock upon initial public offering
Issuance of common stock and warrants in April private placement, net of $1.1 million of offering costs
Issuance of common stock and warrants in August private placement, net of $2.2 million of offering costs
Exercise of stock options
Exercise of pre-funded warrants
Issuance of restricted common stock
Purchase of treasury shares
From June 30, 2022 to September 30, 2022
Exercise of pre-funded warrants
Exercise of stock options
Issuance of common stock and warrants in private placement, net of $2.2 million of offering costs
At the closing of the Private Placement, the Company issued 1,350,000 shares of common stock
From March 31, 2022 to June 30, 2022
Exercise of pre-funded warrants
Issuance of common stock and warrants in private placement, net of $1.1 million of offering costs
From December 31, 2021 to March 31, 2022
Issuance of common stock in initial public offering, net of $2.9 million of offering costs
Conversion of convertible preferred stock to common stock upon initial public offering
1.Common stock offered by company 2,222,222 shares.